Search by Drug Name or NDC

    NDC 70257-0412-87 Lyvispah 5 mg/1 Details

    Lyvispah 5 mg/1

    Lyvispah is a ORAL GRANULE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Saol Therapeutics Inc. The primary component is BACLOFEN.

    Product Information

    NDC 70257-0412
    Product ID 70257-412_4057e10f-332f-48e1-8c97-e80b93331add
    Associated GPIs 75100010003010
    GCN Sequence Number 082876
    GCN Sequence Number Description baclofen GRAN PACK 5 MG ORAL
    HIC3 H6H
    HIC3 Description SKELETAL MUSCLE RELAXANTS
    GCN 51638
    HICL Sequence Number 001949
    HICL Sequence Number Description BACLOFEN
    Brand/Generic Brand
    Proprietary Name Lyvispah
    Proprietary Name Suffix n/a
    Non-Proprietary Name baclofen
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form GRANULE
    Route ORAL
    Active Ingredient Strength 5
    Active Ingredient Units mg/1
    Substance Name BACLOFEN
    Labeler Name Saol Therapeutics Inc
    Pharmaceutical Class GABA A Agonists [MoA], GABA B Agonists [MoA], gamma-Aminobutyric Acid-ergic Agonist [EPC]
    DEA Schedule n/a
    Marketing Category NDA
    Application Number NDA215422
    Listing Certified Through 2024-12-31

    Package

    NDC 70257-0412-87 (70257041287)

    NDC Package Code 70257-412-87
    Billing NDC 70257041287
    Package 90 PACKET in 1 BOTTLE, UNIT-DOSE (70257-412-87) / 1 GRANULE in 1 PACKET
    Marketing Start Date 2021-11-22
    NDC Exclude Flag N
    Pricing Information N/A